Coronary atheroma in patients with PolyVD was resistant to lowering LDL-C <55 mg/dL, and lipoprotein(a) may be a potential therapeutic target to delipidate coronary atheroma.
A. Katasako-Yabumoto, Yu Kataoka, S. Nicholls et al.· Journal of the American Hear...· 0 citations
Background Moderate or severe mitral regurgitation (MR) is common in patients with severe aortic stenosis (AS) treated with transcatheter aortic valve replacement (TAVR). Objectives The objectives of the study was to help define the prevalence and prognosis of persistent MR post-TAVR, particularly in women and in low-f...
Eric D. Warner, S. Harb, Rhonda L. Miyasaka et al.· JACC: Advances· 0 citations
In a national registry, redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR and support redo-TAVR with Evolut as a feasible and effective treatment strategy in appropriately selected patients.
Toby Rogers, V. Bapat, S. Chetcuti et al.· JACC: Cardiovascular Interve...· 1 citation
Women undergoing clinically indicated procedures present with paradoxically less extensive atheroma and more favorable plaque composition despite higher cardiovascular risk burden, and experience greater coronary plaque regression than men after intensive lipid-lowering.
A. Bansal, J. St. John, R. Puri et al.· JACC: Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.